Startups
MacDougall is a strategic communications agency for clients dedicated to delivering new innovations that improve human health. We believe that a communications challenge should never keep you up at night. That’s why we pride ourselves on being your most trusted guide to weather any storm and celebrate every success while pushing the boundaries of conventional approaches to communications. When we work together, we are woven into the fabric of your team to help you achieve your mission, generate attention, move markets, and improve patients’ lives.
Overview
Location
United States, Massachusetts, Natick
Employees
11-50
Founded date
2002
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 21, 2023 | Merck to Acquire Caraway Therapeutics, Inc. | Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases |
| Nov 1, 2023 | Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting | |
| Jul 7, 2023 | Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting | SAN DIEGO, March 14, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancero... |
| May 15, 2023 | Nido Biosciences Emerges as Clinical Stage Company Raising $109 Million to Advance Treatments for Debilitating Neurological Diseases | Leveraging advancements in the understanding of human genetics and disease to develop a sustainable pipeline of novel precision medicines WATERTOWN, Mass.–(BUSINESS WIRE)–May 15, 2023– Nido Biosciences (Nido Bio), a clinical stage company d... |
| May 5, 2023 | Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic | Leiden, The Netherlands, and Heidelberg, Germany, May 2, 2023 – Anavo Therapeutics, a global leader in unlocking the full therapeutic potential of human phosphatase biology, announced today an EUR 8.5 million seed round extension, adding MR... |
| Apr 22, 2023 | Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting | — PRTX007 was shown to be well-tolerated with a favorable safety profile for all analyzed cohorts in the Phase 1 study — |
| Mar 2, 2022 | Caraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD | – Esteemed Harvard Medical School Professor Emeritus and HHMI Investigator, Dr. David Clapham, brings world class expertise on ciliary ion channel biology – |
Reviews 0
FAQ about MacDougall Advisors
When was MacDougall Advisors founded?
MacDougall Advisors was founded in 2002.
What has the press written about MacDougall Advisors?
Parsers VC has collected 8 articles mentioning MacDougall Advisors, among them “Merck to Acquire Caraway Therapeutics, Inc.” (Nov 21, 2023) and “Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AA...” (Nov 1, 2023).
Is MacDougall Advisors still active?
MacDougall Advisors is probably closed: its latest activity on Parsers VC dates from Sep 7, 2024.